Martin Polanco's research while affiliated with Cancer Treatment Centre and other places

Publications (10)

Article
Full-text available
5-MeO-DMT is a psychoactive substance found in high concentrations in the bufotoxin of the Colorado River Toad. Emerging evidence suggests that vaporized 5-MeO-DMT may occasion mystical experiences of comparable intensity to those occasioned by more widely studied psychedelics such as psilocybin, but no empirical study has tested this hypothesis. D...
Article
We examined persisting effects, self-perceived challenges, and potential benefits associated with positive outcomes following ibogaine detoxification using data collected as part of a larger online retrospective study of patients (n=73) who received treatment for chronic opioid use in Mexico between 2012 and 2015. A mixed-methods design was used co...
Article
Full-text available
Opioid use disorder (OUD) is currently an epidemic in the United States (US) and ibogaine is reported to have the ability to interrupt opioid addiction by simultaneously mitigating withdrawal and craving symptoms. This study examined opioid withdrawal and drug craving scores in 50 participants with OUD undergoing a week-long detoxification treatmen...
Chapter
Ibogaine is a plant-derived alkaloid and dissociative psychedelic that demonstrates anti-addictive properties with several substances of abuse, including alcohol. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring psychedelic known to occasion potent mystical-type experiences and also demonstrates anti-addictive properties. The p...
Article
Background and aims: Very few studies have reported the effectiveness of ibogaine as a treatment for chronic opioid use. Therefore, this study evaluated the acute subjective effects of ibogaine, outcomes on problematic opioid consumption, and the long-term associations with psychological functioning. Methods: Using online data collection, 88 pat...
Poster
Full-text available
Background : 5-MeO-DMT is a potent tryptamine found in high concentrations in the venom of the Colorado River Toad. Practical experience suggests that vaporized 5-MeO-DMT may induce mystical experiences that are relatively brief, yet have comparable or greater intensity than those induced by psilocybin. Quantitative evaluations of 5-MeO-DMT induced...
Poster
Full-text available
Human studies on the efficacy of ibogaine in interrupting substance use disorders are limited, and studies on the long-term outcomes are even fewer. Therefore, we designed the current retrospective study to evaluate the subjective effectiveness of ibogaine treatment on problematic opioid consumption, and the long-term associations of treatment with...
Poster
Full-text available
Background: Problematic opioid consumption is currently an epidemic in the United States. Ibogaine is reported to have the ability to interrupt opioid addiction by simultaneously mitigating withdrawal and craving symptoms. Objective: Evaluate opioid withdrawal and drug craving scores using validated clinical instruments in subjects with problematic...

Citations

... Figure 4 compares the Isness-D MEQ30 factor scores to 27 previous studies: 26 studies in the altered states database 28 , where the MEQ30 has been used to analyse YD altered states, and our previous Isness-C study 25 . To analyze these results, we followed the approach Barsuglia et al. 74 used to analyze MEQ30 results obtained during 5-MeO-DMT field tests. Specifically, we undertook comparative analysis of Isness-D to the previously published studies using independent sample t-tests with a significance level of 5% (α = 0.05) calculated using Python (see SM for further details). ...
... In summary, a total of 18 articles were included in the systematic review. Of the 18 selected articles, 15 were case reports or case series (Breuer et al. 2015;Marta et al. 2015;O'Connell et al. 2015;Cloutier-Gill et al. 2016;Hildyard et al. 2016;Meisner et al. 2016;Henstra et al. 2017;Wilkins et al. 2017;Knuijver et al. 2018;Mash et al. 2018;Steinberg and Deyell, 2018;Barsuglia et al. 2018;Grogan et al. 2019;Matamoros-Castillo et al. 2019;Wilson et al. 2021). There were also two randomized, double-blind clinical trials (Glue et al. 2016(Glue et al. , 2015, and one observational study (Brown and Alper, 2018). ...
... Also quantitative results (Brown et al., 2019) sustained ibogaine's psychotropic effects as being psychologically profound, leading to far reaching transformations (pp. 3-4), which is consistent with numerous other studies exploring ibogaine (Naranjo, 1969(Naranjo, , 1974Lotsof and Alexander, 2001;Schenberg et al., 2014;Heink et al., 2017;Camlin et al., 2018;Rodger, 2018) and other hallucinogens' effects, such as DMT, LSD, as well as mescaline (Hood, 1975;Griffiths et al., 2008;MacLean et al., 2011). For an up-todate review of long-term effects associated to psychedelic drugs consumption, see Aday et al. (2020). ...
... Among patients receiving residential psychiatric treatment, grit, a personality trait characterized by perseverance toward long-term goals, has been associated with lower likelihood of past-month heroin use (Griffin et al., 2016). Furthermore, individuals classified as treatment responders during ibogaine-assisted prescription opioid and/or heroin use discontinuation reported experiencing greater inner peace, joy, and sacredness (Davis et al., 2018); likewise, factors including positive affect, meaning-in-life, and self-transcendence mediated the effect of mindfulness training on pain symptoms and analgesic misuse (Garland et al., 2019). Collectively, these findings indicate intrapersonal factors may play an important yet under-appreciated protective role in OUD treatment. ...
... A retrospective open-label study assessed withdrawal symptoms in 50 subjects with OUD 24 and 48 h before and after a one-week detoxification protocol with ibogaine at doses of 18-20 mg/kg. The baseline evaluation showed that the patients had mild to severe withdrawal symptoms and after the one-week intervention protocol, the individuals showed a significant decrease in the related symptoms [145] . An observational open-label study with 191 patients presenting opioid and cocaine withdrawal symptoms according to the ASI and the DSM-IV showed that ibogaine detoxification protocol decreased the depressive symptoms and the craving scores of the individuals, according to the Heroin and Cocaine Craving Questionnaires [146] . ...
... Recent studies showed that taking ibogaine led to a reduction in opiate craving and a reduction in the signs and symptoms of drug withdrawal (Davis et al., 2017;Mash et al., 2018). Furthermore, ibogaine has shown to be a promising treatment for opiate, heroin, cocaine, and alcohol dependence, reducing withdrawal symptoms and promoting continued abstinence (Brown, 2013). ...
... [56][57][58] The primary adverse effects of 5-MeO-DMT include physical effects such as alterations in blood pressure and heart rate, 59 heart palpitations, chest pressure, and physical shaking/ trembling as well as psychological effects including feelings of acute fear, anxiety, sadness, grief, guilt, and near-death type experiences. 50,60 ...
... Ibogaine is a primary alkaloid present in the root bark of the Tabernanthe iboga plant, which has an ancient history of ceremonial use in Central Africa. In recent decades, a number of studies have demonstrated the efficacy of ibogaine in treating opioid dependence (Brown and Alper, 2017;Davis et al., 2017;Malcolm et al., 2018;Noller et al., 2018). The treatment response rates to a single administration of ibogaine in recent observational studies with opioid users are promising. ...